Korro Bio (NASDAQ:KRRO) Price Target Cut to $95.00 by Analysts at Royal Bank of Canada

Korro Bio (NASDAQ:KRRO) had its target price lowered by Royal Bank of Canada from $105.00 to $95.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other analysts also recently weighed in on KRRO. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price target on shares of Korro Bio in a research note on Friday, November 22nd. Oppenheimer began coverage on Korro Bio in a report on Friday, January 10th. They set an “outperform” rating and a $155.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $142.57.

Korro Bio Stock Down 1.9 %

Shares of Korro Bio stock opened at $23.72 on Wednesday. The stock’s fifty day moving average is $30.42 and its two-hundred day moving average is $41.70. Korro Bio has a 52 week low of $18.50 and a 52 week high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07. The company had revenue of $2.27 million during the quarter. As a group, research analysts predict that Korro Bio will post -9.52 EPS for the current year.

Institutional Trading of Korro Bio

Several hedge funds and other institutional investors have recently bought and sold shares of KRRO. KLP Kapitalforvaltning AS purchased a new stake in shares of Korro Bio during the 4th quarter worth $53,000. Quest Partners LLC lifted its position in shares of Korro Bio by 172.1% during the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after buying an additional 1,124 shares during the last quarter. AlphaQuest LLC lifted its position in shares of Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after buying an additional 412 shares during the last quarter. Brown Brothers Harriman & Co. boosted its holdings in shares of Korro Bio by 251.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock valued at $95,000 after buying an additional 2,041 shares in the last quarter. Finally, Vestcor Inc purchased a new position in shares of Korro Bio in the 3rd quarter worth approximately $100,000. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).